Serum Biomarkers for Early Detection of Gynecologic Cancers
Abstract
:1. Introduction
2. Serum Markers for Cervical Cancer
Serum markers | SCC | CYFRA 21-1 | CA 125 | CA 19-9 | CEA | IAP |
Positive rates | squamous | squamous | adeno | adeno | adeno | 43–51% |
28–85% | 42–52% | 27–75% | 35–42% | 26–48% |
Serum markers | M-CSF | YKL-40 | sFas | VEGF | TK |
Positive rates | 27% | squamous adeno | squamous | squamos | N/A |
75% 78% | N/A | N/A |
3. Serum Markers for Endometrial Cancer
Serum markers | CA 125 | CA 19-9 | CA 15-3 | CA 72-4 | CEA | IAP |
Positive rates | 11–43% | 22–24% | 24–32% | 22–32% | 14–22% | 55–76% |
Serum markers | M-CSF | HE4 | sFas | SAA |
Positive rates | 25–73% | E | E | G3-E/S |
46% | N/A | N/A |
Reference | Biomarkers | Sensitivity | Specificity | |||
---|---|---|---|---|---|---|
Zhu et al. (2006)[63] | 13 proteins | 93% | 100% | |||
Farias-Eisner et al. (2009) [61] | 3 proteins | Early Late | Early Late | |||
71% 82% | 88% 86% | |||||
Takano et al. (2009) [62] | 2 proteins | 82% | 86% |
4. Serum Markers for Ovarian Cancer
Serum markers | CA 125 | CA 19-9 | CA 15-3 | CA 72-4 | IAP |
Positive rates | Early Late | M non-M | 50–56% | 63–71% | 70–93% |
50% 92% | 68–83% 28–29% |
Serum markers | HE4 | LPA | sFas |
Positive rates | Early Late | Early Late | N/A |
62–83% 75–93% | 90% 98% |
Reference | Biomarkers | Sensitivity | Specificity | |||
---|---|---|---|---|---|---|
Zhang et al. (2004) [82] | 3 proteins | early | early | |||
83% | 94% | |||||
Su et al. (2007) [83] | 4 proteins | early, M early, all | early, M early, all | |||
95% 89% | 92% 97% | |||||
Nosov et al. (2009) [84] | 4 proteins | early, S early, E | early, S early, E | |||
94% 98% | 94% 98% | |||||
Visintin et al. (2008) [85] | 6 proteins | 95% | 99% |
5. Conclusions
Abbreviations
ApoA-1 | apolipoprotein A-1 |
CA 15-3 | cancer antigen-15-3 |
CA 19-9 | cancer antigen-19-9 |
CA 72-4 | cancer antigen-72-4 |
CA 125 | cancer antigen-125 |
CEA | cancer embryonic antigen |
CIN | cervical intraepithelial neoplasia |
CYFRA 21-1 | cytokeratin 19 fragments |
HE4 | (WFDC2), human epididymis-specific 4-disulfide core protein |
H4 | inter-α-trypsin inhibitor heavy chain fragment |
IAP | immunosuppressive acidic protein |
IGFII | insulin-like growth factor II |
MIF | macrophage inhibitory factor |
LPA | lysophosphatidic acid |
MLRM | multiple logistic regression model |
M-CSF | macrophage colony-stimulating factor |
Pap test | Papanicolaou’s test |
SAA | human serum amyloid A |
SCC | squamous cell carcinoma antigen |
SELDI-TOF-MS | surface-enhanced laser desorption-ionization time-of-flight mass spectrometry |
sFas | serum soluble Fas |
TF | transferrin |
TK | thymidine kinase |
TTR | transthyretin |
TV-USG | transvaginal ultrasonography |
USG | ultrasonography |
VEGF-C | serum isoform of vascular endothelial growth factor |
YKL-40 | (aka CHI3L1) human cartilage glycoprotein-39 |
Acknowledgements
References
- Centers for Disease Control and Prevention. Gynecologic Cancers. Available online: http://www.cdc.gov/cancer/gynecologic/index.htm (accessed on 1 March 2010).
- Nam, J.H.; Chang, K.C.; Chambers, J.T.; Schwartz, P.E.; Cole, L.A. Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers. Gynecol. Oncol. 1990, 38, 66–70. [Google Scholar] [CrossRef]
- Pectasides, D.; Economides, N.; Bourazanis, J.; Pozadzizou, P.; Gogou, L.; Koutsiouba, P.; Athanassiou, A. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer. Am. J. Clin. Oncol. 1994, 17, 307–312. [Google Scholar] [CrossRef]
- DiSaia, P.J.; Creasman, W.T. Clinical Gynecologic Oncology, 6th ed.; Mosby: St. Louis, MO, USA, 2002; pp. 53–112, 137–184, 259–350. [Google Scholar]
- Berek, J.S. (Ed.) Novak's Gynecology, 13th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2002; pp. 1143–1398.
- Scully, R.E.; Young, R.H.; Clement, P.B. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. In Atlas of Tumor Pathology; Third Series, Fascicle 23; AFIP: Washington, DC, USA, 1998; pp. 27–50. [Google Scholar]
- Narimatsu, H.; Sawaki, H.; Kuno, A.; Kaji, H.; Ito, H.; Ikehara, Y. A strategy for discovery of cancer glycol-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 2010, 277, 95–105. [Google Scholar] [CrossRef]
- The American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 109. Clinical Management Guidelines for Obstetricians and Gynecologists. Cervical Cytology Screening. Obstet. Gynecol. 2009, 114, 1409–1420.
- Massuger, L.F.; Koper, N.P.; Thomas, C.M.; Dom, K.E.; Schijf, C.P. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Gynecol. Oncol. 1997, 64, 473–476. [Google Scholar] [CrossRef]
- Lehtovirta, P.; Viinikka, L.; Ylikorkala, O. Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol. Oncol. 1990, 37, 276–278. [Google Scholar] [CrossRef]
- Gadducci, A.; Ferdeghini, M.; Caenaro, G.F.; Prontera, C.; Malagnino, G.; Annichiarico, C.; Chirillo, R.; Bianchi, R.; Fioretti, P. Immunoacid protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA 125 and SCC. Cancer J. 1992, 5, 272–278. [Google Scholar]
- Kainz, C.; Sliutz, G.; Mustafa, G.; Bieglmayr, C.; Koelbl, H.; Reinthaller, A.; Gitsch, G. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. Gynecol. Oncol. 1995, 56, 402–425. [Google Scholar] [CrossRef]
- Micke, O.; Prott, F.J.; Schäfer, U.; Tangerding, S.; Pötter, R.; Willich, N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000, 20, 5113–5115. [Google Scholar]
- Takeda, M.; Sakuragi, N.; Okamoto, K.; Todo, Y.; Minobe, S.; Nomura, E.; Negishi, H.; Oikawa, M.; Yamamoto, R.; Fujimoto, S. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet. Gynecol. Scand. 2002, 81, 451–457. [Google Scholar] [CrossRef]
- Ohara, K.; Tanaka, Y.; Tsunoda, H.; Nishida, M.; Sugahara, S.; Itai, Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet. Gynecol. 2002, 100, 781–787. [Google Scholar] [CrossRef]
- Duk, J.M.; Groenier, K.H.; de Bruijn, H.W.; Hollema, H.; ten Hoor, K.A.; van der Zee, A.G.; Aalders, J.G. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J. Clin. Oncol. 1996, 14, 111–118. [Google Scholar]
- Gadducci, A.; Scambia, G.; Benedetti-Panici, P.; Ferdeghini, M.; Battaglia, F.; Caenaro, G.F.; Foti, E.; Castellani, C.; Cristofani, R.; Facchini, V.; Mancuso, S. The prognostic relevance of pretreatment serum immunosuppressive acidic protein (IAP) in patients with squamous cell carcinoma of the uterine cervix: a comparison with squamous cell carcinoma antigen (SCC). Cancer J. 1994, 7, 241–247. [Google Scholar]
- Gaarenstroom, K.N.; Kenter, G.G.; Bonfrer, J.M.; Korse, C.M.; Van de Vijver, M.J.; Fleuren, G.J.; Trimbos, J.B. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gyneco. Oncol. 2000, 77, 164–170. [Google Scholar] [CrossRef]
- Scambia, G.; Benedetti, P.; Foti, E.; Ferrandina, G.; Leone, F.P.; Marciano, M.; Mancuso, S. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Eur. J. Cancer 1996, 32A, 259–263. [Google Scholar]
- Pras, E.; Willemse, P.H.; Canrinus, A.A.; de Bruijn, H.W.; Sluiter, W.J.; ten Hoor, K.A.; Aalders, J.G.; Szabo, B.G.; de Vries, E.G. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 23–32. [Google Scholar] [CrossRef]
- de Bruijn, H.W.; Duk, J.M.; van der Zee, A.G.; Pras, E.; Willemse, P.H.; Boonstra, H.; Hollema, H.; Mourits, M.J.; de Vries, E.G.; Aalders, J.G. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol. 1998, 19, 505–516. [Google Scholar] [CrossRef]
- Ngan, H.Y.; Cheng, G.T.; Yeung, W.S.; Wong, L.C.; Ma, H.K. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. Gynecol. Oncol. 1994, 52, 63–68. [Google Scholar] [CrossRef]
- Ferdeghini, M.; Gadducci, A.; Annicchiarico, C.; Prontera, C.; Malagnino, G.; Castellani, C.; Facchini, V.; Bianchi, R. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Res. 1993, 13, 1841–1844. [Google Scholar]
- Suzuki, Y.; Nakano, T.; Ohno, T.; Abe, A.; Morita, S.; Tsujii, H. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. J. Cancer Res. Clin. Oncol. 2000, 126, 332–336. [Google Scholar] [CrossRef]
- Gaarenstroom, K.N.; Bonfrer, J.M.; Korse, C.M.; Kenter, G.G.; Kenemans, P. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res. 1997, 17, 2955–2958. [Google Scholar]
- Molina, R.; Filella, X.; Augé, J.M.; Bosch, E.; Torne, A.; Pahisa, J.; Lejarcegui, J.A.; Rovirosa, A.; Mellado, B.; Ordi, J.; Biete, A. CYFRA 21.1 in patients with cervica cancer comparison with SCC and CEA. Anticancer Res. 2005, 25, 1765–1771. [Google Scholar]
- Puthucode-Easwaran, S.; Naik, R.; Athavale, R.; Handley, G.; Lopes, A.; Godfrey, K.; Hatem, M. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report. J. Obstet. Gynaecol. 2005, 25, 486–488. [Google Scholar] [CrossRef]
- Mitsuhashi, A.; Matsui, H.; Usui, H.; Nagai, Y.; Tate, S.; Unno, Y.; Hirashiki, K.; Seki, K.; Shozu, M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann. Oncol. 2009, 20, 71–77. [Google Scholar]
- Ngan, H.Y.; Cheung, A.N.; Lauder, I.J.; Cheng, D.K.; Wong, L.C.; Ma, H.K. Tumour markers and their prognostic value in adenocarcinoma of the cervix. Tumour Biol. 1998, 19, 439–444. [Google Scholar] [CrossRef]
- Leminen, A. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. Gynecol. Oncol. 1990, 39, 358–363. [Google Scholar] [CrossRef]
- Duk, J.M.; Aalders, J.G.; Fleuren, G.J.; Krans, M.; De Bruijn, H.W. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet. Gynecol. 1989, 73, 661–668. [Google Scholar]
- Borras, G.; Molina, R.; Xercavins, J.; Ballesta, A.; Iglesias, J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol. 1995, 57, 205–211. [Google Scholar] [CrossRef]
- Sawada, M.; Okudaira, Y.; Matsui, Y.; Shimizu, Y. Immunosuppressive acidic protein in patients with gynecologic cancer. Cancer 1984, 54, 652–656. [Google Scholar] [CrossRef]
- Battaglia, F.; Scambia, G.; Panici, PB.; Castelli, M.; Ferrandina, G.; Foti, E.; Amoroso, M.; D'Andrea, G.; Mancuso, S. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer. Gynecol. Oncol. 1994, 53, 176–182. [Google Scholar] [CrossRef]
- Suzuki, M.; Ohwada, M.; Sato, I.; Nagatomo, M. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology 1995, 52, 128–133. [Google Scholar] [CrossRef]
- Konno, R.; Takano, T.; Sato, S.; Yajima, A. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin. Cancer Res. 2000, 6, 3576–3580. [Google Scholar]
- Mathur, S.P.; Mathur, R.S.; Gray, E.A.; Lane, D.; Underwood, P.G.; Kohler, M.; Creasman, W.T. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A. Gynecol. Oncol. 2005, 98, 467–483. [Google Scholar] [CrossRef]
- Lebrecht, A.; Ludwig, E.; Huber, A.; Klein, M.; Schneeberger, C.; Tempfer, C.; Koelbl, H.; Hefler, L. Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol. Oncol. 2002, 85, 32–35. [Google Scholar] [CrossRef]
- Fujiwaki, R.; Hata, K.; Moriyama, M.; Iwanari, O.; Katabuchi, H.; Okamura, H.; Miyazaki, K. Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology 2001, 61, 47–54. [Google Scholar]
- Takeshima, N.; Shimizu, Y.; Umezawa, S.; Hirai, Y.; Chen, J.T.; Fujimoto, I.; Yamauchi, K.; Hasumi, K. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol. Oncol. 1994, 54, 321–326. [Google Scholar] [CrossRef]
- Panici, P.B.; Scambia, G.; Baiocchi, G.; Perrone, L.; Greggi, S.; Battaglia, F.; Mancuso, S. Multiple serum markers in patients with endometrial cancer. Gynecol. Obstet. Invest. 1989, 27, 208–212. [Google Scholar] [CrossRef]
- Scambia, G.; Gadducci, A.; Panici, P.B.; Foti, E.; Ferdeghini, M.; Ferrandina, G.; Amoroso, M.; Castellani, C.; Facchini, V.; Mancuso, S. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol. Oncol. 1994, 54, 292–297. [Google Scholar] [CrossRef]
- Hakala, A.; Kacinski, B.M.; Stanley, E.R.; Kohorn, E.I.; Puistola, U.; Risteli, J.; Risteli, L.; Tomás, C.; Kauppila, A. Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. Am. J. Obstet. Gynecol. 1995, 173, 112–119. [Google Scholar] [CrossRef]
- Peters-Engl, C.; Buxbaum, P.; Ogris, E.; Sevelda, P.; Medl, M. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. Anticancer Res. 1998, 18, 4635–4639. [Google Scholar]
- Cherchi, P.L.; Dessole, S.; Ruiu, G.A.; Ambrosini, G.; Farina, M.; Capobianco, G.; Ambrosini, A. The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 1999, 20, 315–317. [Google Scholar]
- Ginath, S.; Menczer, J.; Fintsi, Y.; Ben-Shem, E.; Glezerman, M.; Avinoach, I. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol. Cancer 2002, 12, 372–375. [Google Scholar] [CrossRef]
- Sood, A.K.; Buller, R.E.; Burger, R.A.; Dawson, J.D.; Sorosky, J.I.; Berman, M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet. Gynecol. 1997, 90, 441–447. [Google Scholar] [CrossRef]
- Hsieh, C.H.; ChangChien, C.C.; Lin, H.; Huang, E.Y.; Huang, C.C.; Lan, K.C.; Chang, S.Y. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol. Oncol. 2002, 86, 28–33. [Google Scholar] [CrossRef]
- Gadducci, A.; Cosio, S.; Carpi, A.; Nicolini, A.; Genazzani, A.R. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed. Pharmacother. 2004, 58, 24–38. [Google Scholar] [CrossRef]
- Carpenter, P.M.; Gamboa, G.P.; Dorion, G.E.; Ramsinghani, N.S.; Aïssi, A.M.; Manetta, A. Radiation-induced CA 125 production by mesothelial cells. Gynecol. Oncol. 1996, 63, 328–332. [Google Scholar] [CrossRef]
- Hareyama, H.; Sakuragi, N.; Makinoda, S.; Fujimoto, S. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. J. Clin. Pathol. 1996, 49, 967–970. [Google Scholar] [CrossRef]
- Gadducci, A.; Ferdeghini, M.; Prontera, C.; Giordano, P.; Cristofani, R.; Bianchi, R.; Fioretti, P. A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. Eur. J. Gynaecol. Oncol. 1990, 11, 283–288. [Google Scholar]
- Lo, S.S.; Cheng, D.K.; Ng, T.Y.; Wong, L.C.; Ngan, H.Y. Prognostic significance of tumour markers in endometrial cancer. Tumour Biol. 1997, 18, 241–249. [Google Scholar] [CrossRef]
- Moore, R.G.; Brown, A.K.; Miller, M.C.; Badgwell, D.; Lu, Z.; Granai, C.O.; Bast, R.C., Jr.; Lu, K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008, 110, 196–201. [Google Scholar] [CrossRef]
- Cocco, E.; Bellone, S.; El-Sahwi, K.; Cargnelutti, M.; Buza, N.; Tavassoli, F.A.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 2010, 116, 843–851. [Google Scholar] [CrossRef]
- Chan, D.C.; Chen, C.J.; Chu, H.C.; Chang, W.K.; Yu, J.C.; Chen, Y.J.; Wen, L.L.; Huang, S.C.; Ku, C.H.; Liu, Y.C.; Chen, J.H. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann. Surg. Oncol. 2007, 14, 84–93. [Google Scholar]
- Yokoi, K.; Shih, L.C.; Kobayashi, R.; Koomen, J.; Hawke, D.; Li, D.; Hamilton, S.R.; Abbruzzese, J.L.; Coombes, K.R.; Fidler, I.J. Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int. J. Oncol. 2005, 27, 1361–1369. [Google Scholar]
- Cho, W.C.; Yip, T.T.; Yip, C.; Yip, V.; Thulasiraman, V.; Ngan, R.K.; Yip, T.T.; Lau, W.H.; Au, J.S.; Law, S.C.; Cheng, W.W.; Ma, V.W.; Lim, C.K. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 2004, 10, 43–52. [Google Scholar] [CrossRef]
- Khan, N.; Cromer, C.J.; Campa, M.; Patz, E.F., Jr. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 2004, 101, 379–384. [Google Scholar] [CrossRef]
- Cocco, E; Bellone, S.; El-Sahwi, K.; Cargnelutti, M.; Casagrande, F.; Buza, N.; Tavassoli, F.A.; Siegel, E.R.; Visintin, I.; Ratner, E.; Silasi, D.A.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Serum amyloid A(SAA): a novel biomarker for uterine serous papillary cancer. Br. J. Cancer 2009, 101, 335–341. [Google Scholar] [CrossRef]
- Farias-Eisner, G.; Su, F.; Robbins, T.; Kotlerman, J.; Reddy, S.; Farias-Eisner, R. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am. J. Obstet. Gynecol. 2010, 202, 73.e1–e5. [Google Scholar]
- Takano, M.; Kikuchi, Y.; Asakawa, T.; Goto, T.; Kita, T.; Kudoh, K.; Kigawa, J.; Sakuragi, N.; Sakamoto, M.; Sugiyama, T.; Yaegashi, N; Tsuda, H.; Seto, H; Shiwa, M. Identification of potential serum markers for endometrial cancer using protein expression profiling. J. Cancer Res. Clin. Oncol. 2010, 136, 475–481. [Google Scholar] [CrossRef]
- Zhu, L.R.; Zhang, W.Y.; Yu, L.; Zheng, Y.H.; Zhang, J.Z.; Liao, Q.P. Serum proteomic features for detection of endometrial cancer. Int. J. Gynecol. Cancer 2006, 16, 1374–1378. [Google Scholar] [CrossRef]
- Clarke-Pearson, D.L. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 2009, 361, 170–177. [Google Scholar] [CrossRef]
- Lerner, J.P.; Timor-Tritsch, I.E.; Federman, A.; Abramovich, G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am. J. Obstet. Gynecol. 1994, 170, 81–85. [Google Scholar] [CrossRef]
- Kupesic, S.; Plavsic, B.M. Early ovarian cancer: 3-D power Doppler. Abdom. Imaging. 2006, 31, 613–619. [Google Scholar] [CrossRef]
- Jacobs, I.; Bast, R.C., Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 1989, 4, 1–12. [Google Scholar] [CrossRef]
- Nossov, V.; Amneus, M.; Su, F.; Lang, J.; Janco, J.M.; Reddy, S.T.; Farias-Eisner, R. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 2008, 199, 215–223. [Google Scholar] [CrossRef]
- Kudoh, K.; Kikuchi, Y.; Kita, T.; Tode, T.; Takano, M.; Hirata, J.; Mano, Y.; Yamamoto, K.; Nagata, I. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol. Obstet. Invest. 1999, 47, 52–57. [Google Scholar] [CrossRef]
- Negishi, Y.; Furukawa, T.; Oka, T.; Sakamoto, M.; Hirata, T.; Okabe, K.; Matayoshi, K.; Akiya, K.; Soma, H. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. Gynecol. Obstet. Invest. 1987, 23, 200–207. [Google Scholar] [CrossRef]
- Gadducci, A.; Ferdeghini, M.; Prontera, C.; Moretti, L.; Mariani, G.; Bianchi, R.; Fioretti, P. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol. Oncol. 1992, 44, 147–154. [Google Scholar] [CrossRef]
- Koelma, I.A.; Nap, M.; Rodenburg, C.J.; Fleuren, G.J. The value of tumour marker CA 125 in surgical pathology. Histopathology 1987, 11, 287–294. [Google Scholar] [CrossRef]
- Yedema, C.; Massuger, L.; Hilgers, J.; Servaas, J.; Poels, L.; Thomas, C.; Kenemans, P. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays. Int. J. Cancer 1988, 3, 61–67. [Google Scholar]
- Fioretti, P.; Gadducci, A.; Ferdeghini, M.; Prontera, C.; Malagnino, G.; Facchini, V.; Mariani, G.; Bianchi, R. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol. Oncol. 1992, 44, 155–160. [Google Scholar] [CrossRef]
- Negishi, Y.; Iwabuchi, H.; Sakunaga, H.; Sakamoto, M.; Okabe, K.; Sato, H.; Asano, G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol. Oncol. 1993, 48, 148–154. [Google Scholar] [CrossRef]
- Sawada, M.; Okudaira, Y.; Matsui, Y.; Shimizu, Y. Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 1983, 52, 2081–2085. [Google Scholar] [CrossRef]
- Castelli, M.; Romano, P.; Atlante, G.; Pozzi, M.; Ferrini, U. Immunosuppressive acidic protein (IAP) and CA 125 assays in detection of human ovarian cancer: preliminary results. Int. J. Biol. Markers 1987, 2, 187–190. [Google Scholar]
- Castelli, M.; Battaglia, F.; Scambia, G.; Panici, P.B.; Ferrandina, G.; Mileo, A.M.; Mancuso, S.; Ferrini, U. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer. Oncology 1991, 48, 13–17. [Google Scholar] [CrossRef]
- Li, J.; Dowdy, S.; Tipton, T.; Podratz, K.; Lu, W.G.; Xie, X.; Jiang, S.W. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn. 2009, 9, 555–566. [Google Scholar] [CrossRef]
- Urban, N. Specific keynote: Ovarian cancer risk assessment and the potential for early detection. Gynecol. Oncol. 2003, 88, S75–S79. [Google Scholar] [CrossRef]
- Xu, Y.; Shen, Z.; Wiper, D.W.; Wu, M.; Morton, R.E.; Elson, P.; Kennedy, A.W.; Belinson, J.; Markman, M.; Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280, 719–723. [Google Scholar] [CrossRef]
- Zhang, Z.; Bast, R.C., Jr.; Yu, Y.; Li, J.; Sokoll, L.J.; Rai, A.J.; Rosenzweig, J.M.; Cameron, B.; Wang, Y.Y.; Meng, X.Y.; Berchuck, A.; Van Haaften-Day, C.; Hacker, N.F.; de Bruijn, H.W.; van der Zee, A.G.; Jacobs, I.J.; Fung, E.T.; Chan, D.W. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882–5890. [Google Scholar] [CrossRef]
- Su, F.; Lang, J.; Kumar, A.; Ng, C.; Hsieh, B.; Suchard, M.A.; Reddy, S.T.; Farias-Eisner, R. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2007, 2, 369–375. [Google Scholar]
- Nosov, V.; Su, F.; Amneus, M.; Birrer, M.; Robins, T.; Kotlerman, J.; Reddy, S.; Farias-Eisner, R. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 2009, 200, 639.e1–e5. [Google Scholar]
- Visintin, I.; Feng, Z.; Longton, G.; Ward, D.C.; Alvero, A.B.; Lai, Y.; Tenthorey, J.; Leiser, A.; Flores-Saaib, R.; Yu, H.; Azori, M.; Rutherford, T.; Schwartz, P.E.; Mor, G. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 2008, 14, 1065–1072. [Google Scholar] [CrossRef]
- Anderson, G.L.; McIntosh, M.; Wu, L.; Barnett, M.; Goodman, G.; Thorpe, J.D.; Bergan, L.; Thornquist, M.D.; Scholler, N.; Kim, N.; O'Briant, K.; Drescher, C.; Urban, N. Assessing leadtime of selected ovarian cancer biomarkers: a nested case-control study. J. Natl. Cancer Inst. 2010, 102, 26–38. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Ueda, Y.; Enomoto, T.; Kimura, T.; Miyatake, T.; Yoshino, K.; Fujita, M.; Kimura, T. Serum Biomarkers for Early Detection of Gynecologic Cancers. Cancers 2010, 2, 1312-1327. https://doi.org/10.3390/cancers2021312
Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshino K, Fujita M, Kimura T. Serum Biomarkers for Early Detection of Gynecologic Cancers. Cancers. 2010; 2(2):1312-1327. https://doi.org/10.3390/cancers2021312
Chicago/Turabian StyleUeda, Yutaka, Takayuki Enomoto, Toshihiro Kimura, Takashi Miyatake, Kiyoshi Yoshino, Masami Fujita, and Tadashi Kimura. 2010. "Serum Biomarkers for Early Detection of Gynecologic Cancers" Cancers 2, no. 2: 1312-1327. https://doi.org/10.3390/cancers2021312